Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025PRNewsWire • 08/20/25
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355PRNewsWire • 08/20/25
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline GliomaPRNewsWire • 08/06/25
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View CutZacks Investment Research • 08/06/25
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/25
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial GuidancePRNewsWire • 08/05/25
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to DeclineZacks Investment Research • 07/29/25
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025PRNewsWire • 07/22/25
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract CancerPRNewsWire • 07/01/25
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung CancerPRNewsWire • 06/10/25
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025PRNewsWire • 06/09/25
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPRNewsWire • 06/02/25
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025PRNewsWire • 06/02/25
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025PRNewsWire • 05/29/25